Trial Profile

Single cell characterization of persistent cells upon treatment with durvalumab (MEDI4736) with or without tremelimumab in MSS and MSI colorectal and endometrial tumors

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
Indications Colorectal cancer; Endometrial cancer
Focus Therapeutic Use
Acronyms Serpentine

Most Recent Events

04 Jun 2024 Results(n=24) discussing data of patients (pts) with refractory ICI-naive MSS EC and CRC treated with Dur plus Trem and the characterization of immune and persistent cells with longitudinal single-cell analyses, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
16 Jun 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com